Erratum: Abl inhibitor BMS354825 binding mode in Ableson kinase revealed by molecular docking studies (Leukemia (2005) vol. 19 (1267-1269) 10.1038/sj.leu.2403775);Abl inhibitor BMS354825 binding mode in Abelson kinase revealed by molecular docking studies [3]

Leukemia

Volumn 19, Issue 7, 2005, Pages 1267-1269

  Gambacorti Passerini, C ^a,b   Gasser, M ^c,d   Ahmed, S ^d   Assouline, S ^b   Scapozza, Leonardo ^d  

^a UNIVERSITY OF MILANO BICOCCA   (Italy)

^b MCGILL UNIVERSITY   (Canada)

^c ETH ZURICH   (Switzerland)

^d UNIVERSITY OF GENEVA   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

6 (2,6 DICHLOROPHENYL) 8 METHYL 2 (3 METHYLTHIOANILINO) 8H PYRIDO[2,3 D]PYRIMIDIN 7 ONE; ABELSON KINASE; ANTINEOPLASTIC AGENT; BCR ABL PROTEIN; DASATINIB; IMATINIB; PHOSPHOTRANSFERASE INHIBITOR; UNCLASSIFIED DRUG;

ACCURACY; BINDING ASSAY; CANCER CHEMOTHERAPY; COMPUTER MODEL; COMPUTER PROGRAM; CONTROLLED STUDY; DRUG POTENCY; DRUG PROTEIN BINDING; ENZYME CONFORMATION; HYDROGEN BOND; IC 50; LETTER; MALIGNANT NEOPLASTIC DISEASE; MOLECULAR DYNAMICS; PRIORITY JOURNAL; REPRODUCIBILITY; STRUCTURE ACTIVITY RELATION;

EID: 21744450304     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/sj.leu.2403990     Document Type: Erratum

References (7)

1. Shah NP, Tran C, Lee FY, Chen P, Norris D, Sawyers CL. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 2004; 305: 399-401.
2. Rarey M, Kramer B, Lengauer T, Klebe G. A fast flexible docking method using an incremental construction algorithm. J Mol Biol 1996; 261: 470-489.
3. Nagar B, Bornmann WG, Pellicena P, Schindler T, Veach DR, Miller WT et al. Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571). Cancer Res 2002; 62: 4236-4243.
4. Hubbard SR. Crystal structure of the activated insulin receptor tyrosine kinase in complex with peptide substrate and ATP analog. EMBO J 1997; 16: 5572-5581.
5. Yamaguchi H, Hendrickson WA. Structural basis for activation of human lymphocyte kinase Lck upon tyrosine phosphorylation. Nature 1996; 384: 484-489.
6. Atwell S, Adams JM, Badger J, Buchanan MD, Feil IK, Froning KJ et al. A novel mode of Gleevec binding is revealed by the structure of spleen tyrosine kinase. J Biol Chem 2004; 279: 55827-55832.
7. Corbin AS, Buchdunger E, Pascal F, Druker BJ. Analysis of the structural basis of specificity of inhibition of the Abl kinase by STI571. J Biol Chem 2002; 277: 32214-32219.